Arrowhead Pharmaceuticals

Arrowhead Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in the development of medicines that treat intractable diseases by silencing the genes that cause them. The firms preclinical stage drug candidates include ARO-ANG3, ARO-AAT, ARO-APOC3, ARO-HIF2, ARO-HSD, ARO-Lung2, ARO-COV, and ARO-ENaC. The company was founded by R. Bruce Stewart in 1989 and is headquartered in Pasadena, CA.

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Earnings data Q1 2025

Arrowhead Pharmaceuticals reports strong Q1 earnings and outlines growth strategy

Arrowhead Pharmaceuticals showcased solid financial performance, promising clinical outcomes, and a strategic growth plan during the Q1 2023 earnings call.
While facing challenges in financial losses and program complexities, the company's strengths in innovation, partnerships, and pipeline development position them for future success.
Opportunities lie in upcoming data releases, therapeutic advancements, and strategic collaborations, offering avenues for market expansion and medical breakthroughs.
Overall, Arrowhead Pharmaceuticals demonstrates resilience, innovation, and a clear vision for growth in the competitive biopharmaceutical landscape.

Arrowhead Pharmaceuticals reports robust Q2 earnings and expands pipeline

Arrowhead Pharmaceuticals delivered strong financial results and showcased progress in its drug pipeline, particularly in the pulmonary and CNS spaces.
While facing challenges in translating preclinical success to clinical outcomes and navigating competitive landscapes, the company's strategic partnerships and efficient cost management are key strengths.
Opportunities lie in expanding into new therapeutic areas, leveraging external interest for internal development, and benefiting from regulatory insights in the CNS field.
Overall, Arrowhead Pharmaceuticals remains well-positioned for future growth and innovation in the biopharmaceutical sector.

Arrowhead Pharmaceuticals advances pipeline with strong financial backing

Arrowhead Pharmaceuticals made progress in de-risking its pulmonary franchise and advancing key cardiometabolic candidates.
The company's strong financial position and focus on partnerships support its goal of expanding the pipeline to 20 products by 2025.
Challenges include high operating expenses, the need for specific financing for trials, and managing cash burn effectively.
Exploration of CNS targets and upcoming Phase 2 data presentations offer growth opportunities for Arrowhead Pharmaceuticals.

Arrowhead Pharmaceuticals advances key products towards commercialization amid financial challenges

Arrowhead Pharmaceuticals made significant progress on key products and is advancing towards commercialization and de-risking their pipeline.
Despite facing a net loss, the company remains focused on expanding their product portfolio and exploring new treatment options.
Strategic partnerships and ongoing research efforts position Arrowhead well for future growth and potential commercial success.
Managing financial challenges and optimizing trial strategies will be crucial for Arrowhead's continued success in the biopharmaceutical industry.

Arrowhead Pharmaceuticals advances RNAi pipeline with cardiometabolic focus

Arrowhead Pharmaceuticals focuses on advancing RNAi therapeutics with a cardiometabolic emphasis.
Financials show a net loss with plans to strengthen the balance sheet and decrease operating expenses.
Exploring debt financing, partnerships, and new innovations for pipeline expansion and commercial growth.
Challenges include data delays, uncertain timelines, and the need for additional biomarker data.

Arrowhead Pharmaceuticals reports strong fiscal 2024 results and strategic partnerships

Arrowhead Pharmaceuticals' fiscal 2024 performance was robust, fueled by a game-changing partnership with Sarepta and promising results in the cardiometabolic pipeline.
While facing challenges in differentiation and portfolio management, the company's proactive approach and strong financial position present opportunities for growth and innovation.
Strategic collaborations, ongoing Phase III studies, and plans for debt repayment through partnership cash flows underscore Arrowhead's commitment to value creation and sustainable growth.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Arrowhead Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in the development of medicines that treat intractable diseases by silencing the genes that cause them. The firms preclinical stage drug candidates include ARO-ANG3, ARO-AAT, ARO-APOC3, ARO-HIF2, ARO-HSD, ARO-Lung2, ARO-COV, and ARO-ENaC. The company was founded by Robert Bruce Stewart in 1989 and is headquartered in Pasadena, CA.

Avangrid

SYDNEY--(BUSINESS WIRE)--Canva, the world's leading visual communication platform, continues to experience significant growth in its global K-12 and higher education user base, adding 40 million users in the past year alone. With 70 million teachers and students now onboard, comprising nearly half of Canva's total users, this growth is driven by AI integration and visual communication adoption across prominent institutions like the University of California, New York City Public Schools, and the.

Canva Upskills 70 Million Educators and Students Globally with New Teacher Certification Course

PASADENA, Calif.--(BUSINESS WIRE)---- $arwr--Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced plans to advance investigational plozasiran into a Phase 3 cardiovascular outcomes trial called CAPITAN. This comes after promising results were recently announced from multiple clinical trials in three distinct patient populations, including the pivotal Phase 3 PALISADE study in patients with genetically confirmed or clinically diagnosed familial chylomicronemia syndrome (FCS), the Phase 2 SHASTA-.

Arrowhead Pharmaceuticals to Advance RNAi-based Plozasiran into Phase 3 CAPITAN Cardiovascular Outcomes Trial

PASADENA, Calif.--(BUSINESS WIRE)---- $arwr--Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced that preclinical data on ARO-INHBE, an investigational RNAi-based medicine for the treatment of obesity and metabolic diseases, were presented at the American Diabetes Association (ADA) 84th Scientific Sessions, which were held June 21-24, in Orlando, FL, and virtually. The preclinical results demonstrate that ARO-INHBE substantially silenced hepatic expression of the INHBE gene, which has been ide.

Arrowhead Pharmaceuticals Presents Preclinical Data on New RNAi-Based Obesity Program ARO-INHBE

Merck

Intellia Therapeutics

Verona Pharma

X4 Pharmaceuticals Inc

Biotech stocks are high-risk, high-return opportunities that are under the mercy of several make-or-break catalysts, most of which are binary events. It pays to remain cognizant of the timing of these catalysts and which way they will likely pan out.

5 Biotech Stocks With Key Catalysts This Week: Merck, Intellia, Verona, And More

PASADENA, Calif.--(BUSINESS WIRE)---- $arwr--Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced topline results from the pivotal Phase 3 PALISADE study of investigational plozasiran in patients with genetically confirmed or clinically diagnosed familial chylomicronemia syndrome (FCS), a severe genetic disease with significant unmet need and no FDA approved therapies. PALISADE successfully met the primary endpoint of lowering triglycerides and met all key secondary endpoints, including reducin.

Arrowhead Pharmaceuticals Reports Successful Topline Results for Plozasiran from the Pivotal Phase 3 PALISADE Study in Patients with Familial Chylomicronemia Syndrome

PASADENA, Calif.--(BUSINESS WIRE)---- $arwr--Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced that it is scheduled to participate in the following upcoming events: 16th European Glaucoma Society (EGS) Congress – June 1-4, 2024 Title: Development and Characterization of Trabecular Meshwork Targeted RNAi Molecule Platform via Intracameral Administration for Glaucoma Date/Time: June 2, 2024, 10:30 a.m. IST Session: Poster Section Jefferies Global Healthcare Conference – June 5-6, 2024 Type: Fi.

Arrowhead Pharmaceuticals to Participate in Upcoming June 2024 Conferences

PASADENA, Calif.--(BUSINESS WIRE)---- $arwr--Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced results from the Phase 2b double blind, randomized ARCHES-2 study of investigational zodasiran (formerly ARO-ANG3) in patients with mixed hyperlipidemia. Zodasiran was associated with robust and durable reductions in triglycerides, triglyceride rich lipoprotein remnants, and total atherogenic lipoproteins, including LDL-C. These data were presented in a late-breaking oral presentation today at the.

Arrowhead Pharmaceuticals Presents New Phase 2 Data of Zodasiran in Patients with Mixed Hyperlipidemia

PASADENA, Calif.--(BUSINESS WIRE)---- $arwr--Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced results from the Phase 2b double blind, randomized MUIR study of investigational plozasiran (formerly ARO-APOC3) in patients with mixed hyperlipidemia. Treatment with plozasiran in the MUIR study achieved reductions in triglyceride rich lipoproteins, a genetically validated target associated with increased risk of atherosclerotic cardiovascular disease (ASCVD)1,2. These data were presented in an or.

Arrowhead Pharmaceuticals Presents New Phase 2 Data of Plozasiran in Patients with Mixed Hyperlipidemia

PASADENA, Calif.--(BUSINESS WIRE)---- $arwr--Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced that new interim clinical data on ARO-RAGE, an investigational RNAi-based medicine for the treatment of inflammatory lung diseases, such as asthma, were presented at the American Thoracic Society (ATS) 2024 International Conference. Interim results from the ongoing Phase 1/2 study demonstrate that treatment with ARO-RAGE led to a reduction in soluble RAGE (sRAGE) concentration in bronchoalveolar la.

Arrowhead Pharmaceuticals Presents New Clinical Data Showing ARO-RAGE Achieves High Level of Gene Knockdown in Patients with Asthma

The latest period was a rollercoaster ride for Arrowhead Pharmaceuticals despite significant fundamental developments. Phase 3 results of plozasiran in FCS patients should lead to Arrowhead finally becoming a commercial-stage company in 2025. The bar for plozasiran is set by Ionis' olezarsen in terms of APOC3 and triglyceride reductions as well as the reduction in the risk of acute pancreatitis.

Arrowhead Pharmaceuticals: Focus Turns To Upcoming Pipeline Inflection Point

Joby Aviation

Matthews International

Novocure

Navitas Semiconductor Corp

Viking Therapeutics

YETI

If you're wondering what stocks to buy this month, look no further. Every investor wants their stock picks to double in price.

Double-Up Delights: 7 Stocks Poised to Soar 100% by 2025

Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR ) Q2 2024 Earnings Conference Call May 9, 2024 4:30 PM ET Company Participants Vince Anzalone - VP, IR Chris Anzalone - President and CEO Bruce Given - Chief Medical Scientist James Hamilton - Chief Discovery & Translational Medicine Ken Myszkowski - CFO Conference Call Participants Luca Issi - RBC Capital Edward Tenthoff - Piper Sandler Maury Raycroft - Jefferies Brendan Smith - TD Cowen William Pickering - Bernstein Patrick Trucchio - H.C. Wainwright & Company Operator Ladies and gentlemen, welcome to the Arrowhead Pharmaceuticals Conference Call.

Arrowhead Pharmaceuticals, Inc. (ARWR) Q2 2024 Earnings Call Transcript

PASADENA, Calif.--(BUSINESS WIRE)---- $arwr--Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced financial results for its fiscal 2024 second quarter ended March 31, 2024. The Company is hosting a conference call today, May 9, 2024, at 4:30 p.m. ET to discuss the results. Christopher Anzalone, Ph.D., President and CEO at Arrowhead, said: “Arrowhead has achieved significant progress across our broad pipeline of investigational RNAi-based medicines that leverage the proprietary TRiMTM platform a.

Arrowhead Pharmaceuticals Reports Fiscal 2024 Second Quarter Results

Royalty Pharma

PASADENA, Calif.--(BUSINESS WIRE)---- $arwr--Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced a $50 million milestone payment was received from Royalty Pharma plc (NASDAQ: RPRX). This milestone was triggered after the completion of enrollment of the Phase 3 OCEAN(a) - Outcomes Trial of olpasiran, being conducted by Amgen (NASDAQ: AMGN). Pursuant to its 2016 agreement with Amgen and 2022 agreement with Royalty Pharma, Arrowhead is further eligible to receive up to an additional $375 million.

Arrowhead Pharmaceuticals Earns $50 Million Milestone from Royalty Pharma

PASADENA, Calif.--(BUSINESS WIRE)---- $arwr--Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced that it is scheduled to participate in the following upcoming events: 2024 RBC Capital Markets Global Healthcare Conference – May 14-15, 2024 Type: Fireside Chat Presentation Date/Time: May 14, 2024, 9:30 a.m. EDT BofA Securities 2024 Healthcare Conference – May 13-16, 2024 Type: Fireside Chat Presentation Date/Time: May 16, 2024, 8:40 a.m. PDT TIDES USA 2024 – May 14-17, 2024 Title: Preclinical Pr.

Arrowhead Pharmaceuticals to Participate in Upcoming May 2024 Conferences

PASADENA, Calif.--(BUSINESS WIRE)---- $arwr--Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced its plan to host a 2024 Summer Series of R&D webinars that highlight multiple clinical stage RNA interference (RNAi) based medicines that utilize the company's proprietary Targeted RNAi Molecule (TRiMTM) platform. Each webinar in the Summer Series will focus on a specific therapeutic area and will feature presentations by Arrowhead team members about the company's clinical candidates and extern.

Arrowhead Pharmaceuticals to Host 2024 Summer Series of R&D Webinars

PASADENA, Calif.--(BUSINESS WIRE)---- $arwr--Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced that it will host a webcast and conference call on May 9, 2024, at 4:30 p.m. ET to discuss its financial results for the fiscal second quarter ended March 31, 2024. Webcast and Conference Call and Details Investors may access a live audio webcast on the Company's website at https://ir.arrowheadpharma.com/events-and-presentations. A replay of the webcast will be available approximately two hours aft.

Arrowhead Pharmaceuticals to Webcast Fiscal 2024 Second Quarter Results

PASADENA, Calif.--(BUSINESS WIRE)---- $arwr--Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) announced today that it has dosed the first subjects in a Phase 1/2a clinical trial (NCT06209177) of ARO-CFB, the company's investigational RNA interference (RNAi) therapeutic, in up to 66 healthy volunteers and patients with complement mediated kidney disease. James Hamilton, M.D., MBA, Chief of Discovery and Translational Medicine at Arrowhead, said: “In preclinical studies, ARO-CFB achieved deep and durable red.

Arrowhead Pharmaceuticals Initiates Phase 1/2a Study of ARO-CFB for Treatment of Complement Mediated Kidney Disease

PASADENA, Calif.--(BUSINESS WIRE)---- $arwr--Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today presented final data from the double-blind treatment period of its Phase 2 SHASTA-2 study of investigational plozasiran (formerly ARO-APOC3) in patients with severe hypertriglyceridemia (SHTG). Results from the SHASTA-2 study showed dramatic, consistent, and sustained reductions in Apolipoprotein C-III (APOC3) and triglycerides and improvement in multiple atherogenic lipoprotein levels. These data were prese.

Arrowhead Pharmaceuticals Announces New Phase 2 Data of Plozasiran Published in JAMA Cardiology and Presented at American College of Cardiology 73rd Annual Scientific Session & Expo

Boyd Gaming

Cleveland-Cliffs

Crocs

Healthpeak Properties Inc

Duolingo

Murphy Oil

It may not be much, but the Russell 2000 Index (RUT) is up 7% in 2024. The index still sits about 20% below the all-time high it reached in November 2021.

The 7 Most Undervalued Russell 2000 Stocks to Buy in April 2024

PASADENA, Calif.--(BUSINESS WIRE)---- $arwr--Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced that it has initiated an Expanded Access Program (EAP) to make investigational plozasiran available outside of a clinical trial for patients with familial chylomicronemia syndrome (FCS) who meet certain program eligibility criteria. Arrowhead will also present new final Phase 2 clinical data from the double-blind portion of the SHASTA-2 study of plozasiran in a late-breaking oral presentation at th.

Arrowhead Pharmaceuticals Initiates Expanded Access Program for Plozasiran and Announces Upcoming Presentation of Clinical Data

CRISPR Therapeutics

Cytokinetics

Halozyme Therapeutics

Jazz Pharmaceuticals

SpringWorks Therapeutics Inc

While the technology sector has been enjoying ridiculous returns, it's inevitable that a slowdown (or even a correction) may materialize, which brings to the table biotech stocks. This is just as innovative of sector as “regular” tech but it just hasn't received the same fervor.

7 Biotech Stocks to Buy as Sector Rotation Ramps Up

After closing out 2023 with a 15.1% gain, the Russell 2000 looks even better this year in the new year. In fact, since Jan. 2, the index is up about 4% year to date, and could push even higher, taking some of the most undervalued Russell 2000 stocks along for the ride.

The 3 Most Undervalued Russell 2000 Stocks to Buy in March 2024

PASADENA, Calif.--(BUSINESS WIRE)---- $arwr--Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) announced today that it has dosed the first subjects in a Phase 1/2a double-blinded, placebo-controlled, dose-escalating study (NCT06138743) to evaluate single and multiple ascending doses of ARO-DM1, the company's investigational RNA interference (RNAi) therapeutic, in up to 48 subjects with type 1 myotonic dystrophy (DM1). DM1 is the most common adult-onset muscular dystrophy. Patients with DM1 have muscle weakn.

Arrowhead Pharmaceuticals Initiates Phase 1/2a Study of ARO-DM1 for Treatment of Type 1 Myotonic Dystrophy

PASADENA, Calif.--(BUSINESS WIRE)---- $arwr--Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced that it is scheduled to participate in the following upcoming events: TD Cowen's 44th Annual Health Care Conference – March 6, 2024 Type: Fireside Chat Presentation Date: March 6, 2024 Time: 9:10 a.m. ET Leerink Partners Global Biopharma Conference – March 13, 2024 Type: Fireside Chat Presentation Date: March 13, 2024 Time: 8:00 a.m. ET Presentation materials may be accessed on the Events and Prese.

News for Arrowhead Pharmaceuticals Stock (ARWR)